评估全基因组测序在预测一线抗结核药物敏感性方面的效能
研究纳入2017至2020年1114株结核分枝杆菌复合群分离株,用MGIT960系统做表型药敏试验、全基因组测序预测耐药谱,并实施省略泛敏感株表型药敏的新流程。结果显示WGS对异烟肼、利福平、乙胺丁醇、吡嗪酰胺的基因型敏感预测分别为100%、100%、99.8%、100%,耐药预测分别为98.85%、94.74%、86.96%、75.7%;新流程使88.7%样本免做表型药敏。
要点
- WGS对异烟肼、利福平、乙胺丁醇、吡嗪酰胺的敏感预测为100%、100%、99.8%、100%。
- WGS对上述四药的耐药预测分别为98.85%、94.74%、86.96%、75.7%。
- 新流程使954/1075(88.7%)样本及890/901(98.8%)泛敏感样本免做表型药敏。
核心结论
- 将WGS整合入结核病管理有望替代表型药敏试验,尤其对吡嗪酰胺和乙胺丁醇等难测药物,可能改善治疗结局。
研究设计与样本
- 2017至2020年期间收集1114株结核分枝杆菌复合群分离株,用MGIT960系统做药敏试验,并用WGS预测耐药谱。
- 实施了一种更新的WGS工作流程新算法,对泛敏感株省略表型药敏试验。
主要发现
- 在1075株分析分离株中,WGS对异烟肼、利福平、乙胺丁醇、吡嗪酰胺的基因型敏感预测分别为100%(95%CI 99.6-100%)、100%(95%CI 99.62-100%)、99.8%(95%CI 99.26-99.94%)、100%(95%CI 99.63-100%)。
- WGS基因型耐药预测对异烟肼为98.85%(95%CI 93.77-99.79%),对利福平为94.74%(95%CI 82.71-98.54%),对乙胺丁醇为86.96%(95%CI 67.87-95.46%),对吡嗪酰胺为75.7%(95%CI 59.9-86.63%)。
- 新检测算法使1075份样本中的954份(88.7%)以及901份泛敏感样本中的890份(98.8%)无需进行表型药敏试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to examine the efficacy of whole genome sequencing (WGS) in accurately predicting susceptibility profiles, potentially eliminating the need for conventional phenotypic drug susceptibility testing (pDST) for first-line antituberculosis drugs in routine tuberculosis diagnosis. METHODS: Over the period of 2017 to 2020, 1114 Mycobacterium tuberculosis complex isolates were collected with drug susceptibility testing conducted using the MGIT960 system and WGS performed for predicting drug resistance profiles. In addition, we implemented a new algorithm with an updated WGS workflow, omitting pan-susceptible strains from pDST. RESULTS: Results showed that out of 1075 analysed isolates, WGS-based genotypic sensitivity predictions for isoniazid, rifampicin, ethambutol, and pyrazinamide were 100% (95% CI, 99.6-100%), 100% (95% CI, 99.62-100%), 99.8% (95% CI, 99.26-99.94%), and 100% (95% CI, 99.63-100%), respectively. In contrast, the WGS-based genotypic resistance prediction, was 98.85% (95% CI, 93.77-99.79%) for isoniazid, 94.74% (95% CI, 82.71-98.54%) for rifampicin, 86.96% (95% CI, 67.87-95.46%) for ethambutol, and 75.7% (95% CI, 59.9-86.63%) for pyrazinamide. Moreover, WGS enabled the implementation of a new testing algorithm that made it unnecessary to perform pDST in 954 of all 1075 samples (88.7%) and in 890 of 901 pan-susceptible samples (98.8%). DISCUSSION: Integrating WGS into tuberculosis management offers significant potential to replace phenotypic drug susceptibility testing, especially for problematic drugs like pyrazinamide and ethambutol, potentially improving treatment outcomes.
引用
- Ghodousi A, Omrani M, Torri S, et al. Evaluating the efficacy of whole genome sequencing in predicting susceptibility profiles for first-line antituberculosis drugs. Clin Microbiol Infect. 2024. PMID: 39341416. doi:10.1016/j.cmi.2024.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。